Search

Single dose slow-release vaccines herald a new era in vaccine administration. An ideal device for slow-release vaccine delivery would be minimally invasive and self-administered, making these approaches an attractive alternative for mass vaccination programs, particularly during the time of a pandemic. In this review article, we discuss the latest advances in this field, specifically for prophylactic vaccines able to prevent infectious diseases. Recent studies have found that slow-release vaccines elicit better immune responses and often do not require cold chain transportation and storage, thus drastically reducing the cost, streamlining distribution, and improving efficacy. This promise has attracted significant attention, especially when poor patient compliance of the standard multidose vaccine regimes is considered. Single dose slow-release vaccines are the next generation of vaccine tools that could overcome most of the shortcomings of present vaccination programs and be the next platform technology to combat future pandemics. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Implantable Materials and Surgical Technologies > Nanomaterials and Implants Biology-Inspired Nanomaterials > Protein and Virus-Based Structures.

Prophylactic vaccines capable of preventing human papillomavirus (HPV) infections are still inaccessible to a vast majority of the global population due to their high cost and challenges related to multiple administrations performed in a medical setting. In an effort to improve distribution and administration, we have developed dissolvable microneedles loaded with a thermally stable HPV vaccine candidate consisting of Qβ virus-like particles (VLPs) displaying a highly conserved epitope from the L2 protein of HPV (Qβ-HPV). Polymeric microneedle delivery of Qβ-HPV produces similar amounts of anti-HPV16 L2 IgG antibodies compared to traditional subcutaneous injection while delivering a much smaller amount of intradermal dose. However, a dose sparing effect was found. Furthermore, immunization yielded neutralizing antibody responses in a HPV pseudovirus assay. The vaccine candidate was confirmed to be stable at room temperature after storage for several months, potentially mitigating many of the challenges associated with cold-chain distribution. The ease of self-administration and minimal invasiveness of such microneedle patch vaccines may enable wide-scale distribution of the HPV vaccine and lead to higher patient compliance. The Qβ VLP and its delivery technology is a plug-and-play system that could serve as a universal platform with a broad range of applications. Qβ VLPs may be stockpiled for conjugation to a wide range of epitopes, which are then packaged and delivered directly to the patient via noninvasive microneedle patches. Such a system paves the way for rapid distribution and self-administration of vaccines.

Human papillomavirus (HPV) is a globally prevalent sexually-transmitted pathogen, responsible for most cases of cervical cancer. HPV vaccination rates remain suboptimal, partly due to the need for multiple doses, leading to a lack of compliance and incomplete protection. To address the drawbacks of current HPV vaccines, we used a scalable manufacturing process to prepare implantable polymer-protein blends for single-administration with sustained delivery. Peptide epitopes from HPV16 capsid protein L2 were conjugated to the virus-like particles derived from bacteriophage Qβ, to enhance their immunogenicity. The HPV-Qβ particles were then encapsulated into poly(lactic-co-glycolic acid) (PLGA) implants, using a benchtop melt-processing system. The implants facilitated the slow and sustained release of HPV-Qβ particles without the loss of nanoparticle integrity, during high temperature melt processing. Mice vaccinated with the implants generated IgG titers comparable to the traditional soluble injections and achieved protection in a pseudovirus neutralization assay. HPV-Qβ implants offer a new vaccination platform; because the melt-processing is so versatile, the technology offers the opportunity for massive upscale into any geometric form factor. Notably, microneedle patches would allow for self-administration in the absence of a healthcare professional, within the developing world. The Qβ technology is highly adaptable, allowing the production of vaccine candidates and their delivery devices for multiple strains or types of viruses.

The effluent contains many harmful microbes which should be eliminated before it is discharged into a water body. Silver nanoparticles (AgNPs) being high-quality significance and have a great impact on this research field as it inhibits microbial proliferation and infection. Therefore, it may use for Bioremediation purposes, our laboratory is fascinated by the production of polymer matrix entrapment silver nanoparticles for in situ bio-remediation purposes. The AgNPs was prepared from sawdust by decoction method. The yellowish solution turns into dark brown colour indicating the formation of AgNPs. A sharp SPR (Surface Plasmon Resonance) band formation in UV-vis spectroscopy scan establishes the formation and stability of silver nanoparticles in an aqueous solution. SEM microphotograph indicated roughly spheroidal structure with (63±3) nm average diameters of newly synthesized AgNp. Polyvinyl alcohol (PVA) is eco-friendly and non-toxic to the environment was chosen for the preparation of polymeric matrix. The non-toxic concentration (1 μg/mL) of AgNp was dispersed into PVA solution followed by cross-linked with maleic acid. PVA- maleic acid is cross-linked by the formation of an ester bond, whereas silver nanoparticles physically entrap into the cross-linked matrix. The silver nanoparticles were released from the matrix nearly after 10 min of swelling of the composite film. In a microbial assay using E. coli agar medium, PVA-AgNp composite film shows the significant killing of microorganisms. Microbial elimination is measured indirectly by pH measurement and dissolved oxygen concentration measurement of the effluent in situ against RO- water, taken as control. The dissolved oxygen concentration from RO water and effluent water was measured on Day "0" followed by treatment and incubation at the BOD chamber. The treatment with PVA-AgNp composite film reduced the BOD Level and increase dissolved oxygen level simultaneously increasing the quality of water. [ABSTRACT FROM AUTHOR]